A randomized first-in-human phase I trial of differentially adjuvanted Pfs48/45 malaria vaccines in Burkinabé adults
Journal of Clinical Investigation · 01.04.2024 · 134 (7)
DOI: 10.1172/jci175707 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Journal of Clinical Investigation, online erschienen am 01.04.2024. Verfasst von Alfred B Tiono und 25 weiteren Autor:innen. Beteiligte Einrichtung: Groupe de Recherche Action en Santé (GRAS), Ouagadougou, Burkina Faso. Hauptthemen laut MEDLINE: Malaria Vaccines, Malaria, Malaria, Falciparum. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union and Developing Countries Clinical Trials Partnership.
Abstract (Originalsprache)
BACKGROUND Malaria transmission-blocking vaccines aim to interrupt the transmission of malaria from one person to another. METHODS The candidates R0.6C and ProC6C share the 6C domain of the Plasmodium falciparum sexual-stage antigen Pfs48/45. R0.6C utilizes the glutamate-rich protein (GLURP) as a carrier, and ProC6C includes a second domain (Pfs230-Pro) and a short 36–amino acid circumsporozoite protein (CSP) sequence. Healthy adults ( n = 125) from a malaria-endemic area of Burkina Faso were immunized with 3 intramuscular injections, 4 weeks apart, of 30 μg or 100 μg R0.6C or ProC6C each adsorbed to Alhydrogel (AlOH) adjuvant alone or in combination with Matrix-M (15 μg or 50 μg, respectively). The allocation was random and double-blind for this phase I trial. RESULTS The vaccines were safe and well tolerated with no vaccine-related serious adverse events. A total of 7 adverse events, mild to moderate in intensity and considered possibly related to the study vaccines, were recorded. Vaccine-specific antibodies were highest in volunteers immunized with 100 μg ProC6C-AlOH with Matrix-M, and 13 of 20 (65%) individuals in the group showed greater than 80% transmission-reducing activity (TRA) when evaluated in the standard membrane feeding assay at 15 mg/mL IgG. In contrast, R0.6C induced sporadic TRA. CONCLUSION All formulations were safe and well tolerated in a malaria-endemic area of Africa in healthy adults. The ProC6C-AlOH/Matrix-M vaccine elicited the highest levels of functional antibodies, meriting further investigation. TRIAL REGISTRATION Pan-African Clinical Trials Registry (https://pactr.samrc.ac.za) PACTR202201848463189. FUNDING The study was funded by the European and Developing Countries Clinical Trials Partnership (grant RIA2018SV-2311).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Groupe de Recherche Action en Santé (GRAS), Ouagadougou, Burkina Faso.
- Department for Congenital Disorders, Statens Serum Institut (SSI), Copenhagen, Denmark.
- Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.
- Centre for Medical Parasitology at Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.
- Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Legon, Accra, Ghana.
- Novavax AB, Uppsala, Sweden.
Förderung
- European Union and Developing Countries Clinical Trials Partnership
Zitieren
APA
Tiono, A. B., Plieskatt, J. L., Ouedraogo, A., Soulama, B. I., Miura, K., Bougouma, E. C., Naghizadeh, M., Barry, A., Yaro, J. B. B., Ezinmegnon, S., Henry, N., Ofori, E. A., Adu, B., Singh, S. K., Konkobo, A., Lövgren Bengtsson, K., Diarra, A., Carnrot, C., Reimer, J. M., …, & Theisen, M. (2024). A randomized first-in-human phase I trial of differentially adjuvanted Pfs48/45 malaria vaccines in Burkinabé adults. Journal of Clinical Investigation, 134(7). https://doi.org/10.1172/jci175707
Vancouver
Tiono AB, Plieskatt JL, Ouedraogo A, Soulama BI, Miura K, Bougouma EC, et al. A randomized first-in-human phase I trial of differentially adjuvanted Pfs48/45 malaria vaccines in Burkinabé adults. Journal of Clinical Investigation. 2024;134(7). doi:10.1172/jci175707
BibTeX
@article{Tiono2024,
author = {Tiono, Alfred B and Plieskatt, Jordan L and Ouedraogo, Alphonse and Soulama, Ben Idriss and Miura, Kazutoyo and Bougouma, Edith C and Naghizadeh, Mohammad and Barry, Aissata and Yaro, Jean Baptist B and Ezinmegnon, Sem and Henry, Noelie and Ofori, Ebenezer Addo and Adu, Bright and Singh, Susheel K and Konkobo, Augustin and Lövgren Bengtsson, Karin and Diarra, Amidou and Carnrot, Cecilia and Reimer, Jenny M and Ouedraogo, Amidou and Tienta, Moussa and Long, Carole A and Ouedraogo, Issa N and Sagara, Issaka and Sirima, Sodiomon B and Theisen, Michael},
title = {A randomized first-in-human phase I trial of differentially adjuvanted Pfs48/45 malaria vaccines in Burkinabé adults},
journal = {Journal of Clinical Investigation},
year = {2024},
volume = {134},
number = {7},
doi = {10.1172/jci175707}
}
EUVIMED